German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...

BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...

BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...

BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

The German biotech firm reaffirmed its full-year guidance and reported lower operating expenses alongside a solid cash ...

Investing.com - ブリストル・マイヤーズ・スクイブ・カンパニーは、成長ポートフォリオ全体の好調な業績に支えられ、アナリスト予想を上回る第2四半期決算を発表し、通期ガイダンスを引き上げた。この発表を受け、同社株価は2.2%上昇した。

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antib ...